Truth Seeker
New Member
Takeda has moved its potential first-in-class diabetes candidate TAK-875 into phase III clinical trials.
The company hopes TAK-875 will offer type II diabetic patients with improved glycaemic control and a low risk of inducing hypoglycaemia.
"TAK-875 is the first GPR-40 agonist to reach clinical development and expected to be a novel treatment option," said Nancy Joseph-Ridge, corporate officer and general manager of Takeda's Pharmaceutical Development Division.
"We are developing TAK-875 globally, with Japan being the first region to begin phase III trials. By doing so, this will provide a new diabetes treatment option for patients and healthcare professionals as efficiently as possible."
The company has started three phase III trials of TAK-875, whose novel method of action sees it target G-protein-coupled receptors (GPCR) expressed in pancreatic islet cells.
GPCRs are cell surface receptors involved in a variety of important physiological activity in the cells, including controlling blood pressure and blood glucose levels.
TAK-875 works by increasing insulin secretion in a glucose-dependent manner, which is different from the mechanisms of sulfonylurea.
Takeda's phase III clinical trials programme for the drug includes a multi-centre, double-blind controlled trial which will evaluate the efficacy and safety of TAK-875, orally administered, compared to placebo.
The study will be conducted in patients with type II diabetes who are not achieving adequate glycaemic control through diet and exercise therapies alone.
In June Takeda released phase II trial results for TAK-875 that showed significantly greater HbA1c reductions after 12 weeks, compared to placebo, and comparable level of decrease comparable to glimepiride (marketed as Amaryl by Sanofi and Glimy by Dr Reddy's Laboratories).
The results also showed the incidence of hypoglycaemia was significantly lower for TAK-875 (2.3%) compared to the sulfonylurea glimepiride (16.1%) and similar to placebo (3.3%).
Source: Takeda moves potential first-in-class diabetes drug into phase III | InPharm
The company hopes TAK-875 will offer type II diabetic patients with improved glycaemic control and a low risk of inducing hypoglycaemia.
"TAK-875 is the first GPR-40 agonist to reach clinical development and expected to be a novel treatment option," said Nancy Joseph-Ridge, corporate officer and general manager of Takeda's Pharmaceutical Development Division.
"We are developing TAK-875 globally, with Japan being the first region to begin phase III trials. By doing so, this will provide a new diabetes treatment option for patients and healthcare professionals as efficiently as possible."
The company has started three phase III trials of TAK-875, whose novel method of action sees it target G-protein-coupled receptors (GPCR) expressed in pancreatic islet cells.
GPCRs are cell surface receptors involved in a variety of important physiological activity in the cells, including controlling blood pressure and blood glucose levels.
TAK-875 works by increasing insulin secretion in a glucose-dependent manner, which is different from the mechanisms of sulfonylurea.
Takeda's phase III clinical trials programme for the drug includes a multi-centre, double-blind controlled trial which will evaluate the efficacy and safety of TAK-875, orally administered, compared to placebo.
The study will be conducted in patients with type II diabetes who are not achieving adequate glycaemic control through diet and exercise therapies alone.
In June Takeda released phase II trial results for TAK-875 that showed significantly greater HbA1c reductions after 12 weeks, compared to placebo, and comparable level of decrease comparable to glimepiride (marketed as Amaryl by Sanofi and Glimy by Dr Reddy's Laboratories).
The results also showed the incidence of hypoglycaemia was significantly lower for TAK-875 (2.3%) compared to the sulfonylurea glimepiride (16.1%) and similar to placebo (3.3%).
Source: Takeda moves potential first-in-class diabetes drug into phase III | InPharm
